News
March 8, 2024
UPDATE: Investigational New Drug, ATA3219, Receives FDA Approval for Lupus Nephritis Treatment Study
The new drug application for the investigational therapy, ATA3219, for treatment of systemic lupus erythematosus (SLE) with kidney involvement (lupus nephritis) was approved for study by the U.S. Food and Drug Administration. The first trial participants are expected to be enrolled in the second half of 2024. Continue to follow the Lupus Foundation of America for updates on lupus drug developments and clinical trials. Learn more about treatments being studied for lupus.
See More:
Get Lupus Research Headlines Emailed to You
Interested in getting research like this straight to your inbox? Subscribe to our bimonthly Inside Lupus Research email for all the latest.
The latest from Inside Lupus Research
News
Differences in Disease Activity by Onset-Age in People with Systemic Lupus Erythematosus
News
Study Reveals Depression is Often Undiagnosed in People with Systemic Lupus Erythematosus
News
Neighborhood Disadvantage Associated with Lower Testing and Physician Access in Young People with Systemic Lupus Erythematosus Despite Insurance Coverage
News
Drug Update: First Person Dosed with Investigational Therapy AlloNK for Lupus Nephritis